The $22 million investment from ATAI will develop the drug ibogaine which is derived from the iboga plant that has previously been sold as a stimulant …
A joint venture has been set up by ATAI Life Sciences and DemeRX to develop a one and done treatment that will work to give people suffering from addiction a neurochemical reset of sorts using a drug derived from a Western African plant.
The $22 million investment from ATAI will develop the drug ibogaine which is derived from the iboga plant that has previously been sold as a stimulant ...
Ibogaine Treatment and the Opioid Crisis: Past, Present, and Future
Thomas Kingsley Brown, Ph.D.
The Sleeping Octopus Assembly on Psychedelics (SOAP) is an intimate conference that explored the role of psychedelics in science, medicine, policy, and culture, which took place at a historic mansion in Pittsburgh, Pennsylvania, from July 13-15, 2018.
This conference featured presentations from key figures in the psychedelic research and policy community, a psychedelic-themed comedy show, ...
Learn more and donate: http://www.maps.org/
Geoff Noller, PhD, and Thomas Kingsley Brown, PhD
moderated by Clare Wilkins
Insights from Contemporary
Ibogaine Research for Addiction
2017 Psychedelic Science Conference
A six-day global gathering of the international scientific community in Oakland, California to explore new research into the benefits and risks of MDMA, LSD, psilocybin, ayahuasca, ketamine, ibogaine, medical marijuana, and more.
Help us caption and translate this video on Amara.org: http://www.amara.org/en/videos/ypBoaytF37qb/info/
Results of the Long-Term Outcomes Study of Ibogaine Treatment in Mexico
Thomas Kingsley Brown, PhD
This presentation is an overview of the MAPS-funded study of long-term outcomes for ibogaine-assisted treatment of opiate dependence for patients at two clinics in Baja California, Mexico. Beginning in September of 2010, the study enrolled thirty US residents seeking ibogaine treatment for opiate dependence at ...